Hanmi’s U.S. partner starts phase-2 trial for long-acting LAPS-GCSF in patients with breast cancer
Hanmi Pharmaceutical Co. said Tuesday that its U.S. partner Spectrum Pharmaceuticals has initiated a Phase-2 clinical program for SPI-2012 (also referred to as “LAPS-GCSF”), a drug candidate for ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
